Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Exelixis |
---|---|
Information provided by: | Exelixis |
ClinicalTrials.gov Identifier: | NCT00491699 |
The purpose of this study is to determine the safest dose of XL999 and how well subjects with Non-Small-Cell Lung Cancer tolerate XL999. XL999 is a small molecule inhibitor of multiple kinases including VEGFR, PDGFR, FGFR, FLT-3, and Src, which are involved in tumor cell growth, formation of new blood vessels (angiogenesis), and metastasis.
Condition | Intervention | Phase |
---|---|---|
Non-Small-Cell Lung Cancer |
Drug: XL999 |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety Study |
Official Title: | A Phase 1 Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL999 Administered Intravenously to Subjects With Non-Small-Cell Lung Cancer (NSCLC) |
Estimated Enrollment: | 70 |
Study Start Date: | August 2007 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
The subject has had no other diagnosis of malignancy (unless non-melanoma skin cancer, in situ carcinoma of the cervix, or a malignancy diagnosed
Exclusion Criteria:
The subject has uncontrolled and/or intercurrent illness including but not limited to the following:
Cardiac:
Vascular:
Hematologic:
Recent surgical procedures:
Wound healing problems:
United States, California | |
UCLA Medical Center | |
Los Angeles, California, United States, 90095 | |
United States, Georgia | |
Peachtree Hematology Oncology Consultants | |
Atlanta, Georgia, United States, 30309 | |
United States, Michigan | |
Wayne State University, Karmanos Cancer Institute | |
Detroit, Michigan, United States, 48201 | |
United States, New York | |
Hematology-Oncology Associates of Rockland | |
Nyack, New York, United States, 10960 |
Study ID Numbers: | XL999-002 |
Study First Received: | June 22, 2007 |
Last Updated: | April 23, 2008 |
ClinicalTrials.gov Identifier: | NCT00491699 History of Changes |
Health Authority: | United States: Food and Drug Administration |
NSCLC |
Thoracic Neoplasms Respiratory Tract Diseases Lung Neoplasms Lung Diseases |
Non-small Cell Lung Cancer Carcinoma, Non-Small-Cell Lung Neoplasms, Glandular and Epithelial Carcinoma |
Thoracic Neoplasms Respiratory Tract Neoplasms Neoplasms Neoplasms by Site Neoplasms by Histologic Type Respiratory Tract Diseases |
Lung Neoplasms Lung Diseases Carcinoma, Non-Small-Cell Lung Neoplasms, Glandular and Epithelial Carcinoma |